← Leaderboards
Adel Nefzi
Torrey Pines Inst For Molecular Studies
$3,769,588
Attributed
$6,958,462
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,958,462 · 9
By mechanism
R01$3,094,096 · 1
R21$1,713,083 · 4
R33$921,907 · 1
R61$479,375 · 1
R03$450,000 · 1
R41$300,001 · 1
Top collaborators
- F Javier Piedrafita7 shared
- Jay P Mclaughlin5 shared
- Colette Dooley2 shared
- Fenfei Leng2 shared
- Andrew V Oleinikov2 shared
- Kyle H Rohde2 shared
- Madepalli Krishnappa Lakshmana1 shared
Others in their field
Top investigators on “Libraries”
- David Heimbrook · Leidos Biomedical Research, Inc.$860,725,506
- Leonard Freedman · Leidos Biomedical Research, Inc.$792,858,643
- Richard A Gibbs · Baylor College Of Medicine$428,954,539
- Lynn Briscoe · Leidos Biomedical Research, Inc.$225,263,761
- Leonard Freedmand · Leidos Biomedical Research, Inc.$160,413,316
- Robert H Waterston · Washington University$155,287,704
Research focus
LibrariesIn VivoIn VitroSmall MoleculeBasePharmaceutical PreparationsLeadMediatingBindingInterestCellsInnovationSeriesScreeningReceptorPreventSmall Molecule LibrariesHigh Throughput ScreeningDesignPropertyDrug KineticsMeasurementAlzheimer&AposInhibitor/Antagonist
Grant awards (21)
Effect of small molecule activator of autophagy on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease$479,375
R61 · FY2025 · AG
Novel gyrase inhibitors targeting Mycobacterium tuberculosis$186,265
R21 · FY2024 · AI
Novel gyrase inhibitors targeting Mycobacterium tuberculosis$235,375
R21 · FY2023 · AI
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$297,085
R33 · FY2022 · DA · contact PI
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$304,664
R33 · FY2021 · DA · contact PI
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$316,935
R33 · FY2020 · DA · contact PI
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$3,223
R33 · FY2020 · DA · contact PI
High throughput screening for anti-adhesion drugs against placental and cerebral malaria$253,125
R21 · FY2019 · AI
Novel RORgamma antagonists for inflammation and autoimmune disease$489,026
R01 · FY2018 · AI · contact PI
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$376,000
R21 · FY2018 · DA · contact PI
High throughput screening for anti-adhesion drugs against placental and cerebral malaria$223,313
R21 · FY2018 · AI
Novel RORgamma antagonists for inflammation and autoimmune disease$97,667
R01 · FY2018 · AI · contact PI
Novel RORgamma antagonists for inflammation and autoimmune disease$584,371
R01 · FY2017 · AI · contact PI
Identification of Small Molecule Amyloid Beta Peptide Reducing Agent$300,001
R41 · FY2017 · AG · contact PI
Novel RORgamma antagonists for inflammation and autoimmune disease$590,333
R01 · FY2016 · AI
LMTK3 inhibitors for the treatment of breast cancer$199,275
R21 · FY2016 · CA
Novel RORgamma antagonists for inflammation and autoimmune disease$580,731
R01 · FY2015 · AI
LMTK3 inhibitors for the treatment of breast cancer$239,730
R21 · FY2015 · CA
Novel RORgamma antagonists for inflammation and autoimmune disease$751,968
R01 · FY2014 · AI
Innovative approaches to oligoheterocyclic peptidomimetics$225,000
R03 · FY2010 · DA · contact PI
Innovative approaches to oligoheterocyclic peptidomimetics$225,000
R03 · FY2009 · DA · contact PI